Biosyent Q1 2017 Results
TORONTO, ONTARIO--(Marketwired - May 25, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include: First quarter (Q1) 2017 Net Revenues of $3,821,262 increased by 1% versus Q1 2016 Q1 2017 Pharmaceutical Net Revenues of $3,652,834 increased by 3% versus Q1 2016 with Canadian Pharmaceutical Net Revenues of $3,354,697 increasing by 2% versus Q1 2016 and International Pharmaceutical Net Revenues of $298,137 increasing by 17% versus Q1 2016 Q1 2017 EBITDA 1 of $1,191,324 decreased by 6% versus Q1 2016 Q1 2017 Net Income After Tax (NIAT) of $901,556 decreased by 5% versus Q1 2016 Q1 2017 NIAT percentage to Net Revenues of 24% compares to 25% in Q1 2016 Q1 2017 Fully Diluted EPS was $0.06 as compared to $0.07 in Q1 2016 Trailing Twelve Months Fully Diluted EPS was $0.29 for the twelve months ended March 31, 2017 as compared to $0.26 for the twelve months en